33results about How to "Improve coagulation function" patented technology

The invention provides a terpenoid shown by the formula I or pharmaceutically acceptable salt, ester or hydrate thereof. The invention also provides a preparation and application of the terpenoid. In the invention, a carbon-drop diterpene new compound separated from leonurus is carbon-drop labdane diterpene obtained from the nature for the first time. The compound can obviously shorten the PT (prothrombin time), APTT (activated partial thromboplastin time) and TT (thrombin time) in vitro and obviously increase the amount of FIB (fibrinogen) in blood, and realizes a certain effect on enhancing the coagulation function, thereby providing a new option for developing a novel natural coagulation drug.

The invention relates to a traditional Chinese medicine pill for curing amenorrhea resulted from psychotropic drugs and a preparation method thereof. The traditional Chinese medicine pill is prepared from the following bulk drugs in parts by weight: 80-100 parts of salvia miltiorrhiza bunge, 80-100 parts of peach kernel, 80-100 parts of safflower, 30-40 parts of cinnamon, 30-40 parts of fennel, 40-60 parts of folium artemisiae argyi, 40-60 parts of rhizoma cyperi, 40-60 parts of radix linderae, 40-60 parts of angelica sinensis, 40-60 parts of szechuan lovage rhizome, 40-60 parts of twotooth achyranthes root, 40-50 parts of rhizoma corydalis, 40-60 parts of bighead atractylodes rhizome and 40-60 parts of poria. The preparation method is as follows: weighting and processing 900g of the bulk drugs in parts by weight; taking 600g of the processed bulk drugs, adding 1200ml of water in the 600g of the processed bulk drugs, decocting for 40 minutes, removing dregs, decocting once again until the decoction liquid boils, decocting by slow fire and concentrating until the volume of the decoction solution is 400ml for later use; and grinding the rest 300g of the bulk drugs into fine powder, and placing the fine powder in a pelleting container, spraying the concentrated liquid in the pelleting container to prepare into water pills, taking the water pills out of the container and drying to obtain the concentrated pills. The traditional Chinese medicine pill is a pure traditional Chinese medicine preparation, has no toxic or side effect, is convenient to take and has low price.

The invention relates to the technical field of disinfection wet wipes, and discloses a medical disinfection wet wipe which is prepared by the following steps: reacting cellulose with epoxy chloropropane to obtain epoxidized cellulose, reacting the epoxidized cellulose with 1, 10-decanediol to obtain hydroxylated alkyl modified cellulose, reacting with the hydroxylated alkyl modified cellulose to obtain chloroalkylated cellulose, and further reacting the chloroalkylated cellulose with N,N-dimethyl dodecylamine to obtain obtain quaternary ammonium salt modified alkylated cellulose, dissolving the quaternary ammonium salt modified alkylated cellulose in ethanol to form an antibacterial solution, and infiltrating a non-woven fabric in the antibacterial solution to obtain the medical disinfection wet tissue capable of promoting wound healing. The cellulose can stimulate the proliferation of local tissue cells in the wound, which is conducive to wound healing. A long alkyl chain is introduced into a cellulose matrix, so that the adhesion of cellulose can be improved, the rapid hemostasis effect is achieved, quaternary ammonium salt can promote bacterial cell protein to be denatured and destroy the interiors of cells, and then growth and reproduction of bacteria are inhibited, so that the disinfection and antibacterial performance of the medical disinfection wet tissue is enhanced.

The invention discloses a chitosan/ Curdlan blended membrane material which takes chitosan and Curdlan as base materials and takes glycerol, pentaerythritol and xylitol or sorbitol as crosslinker to be prepared by a solution blending method, wherein the feeding mass ratio of chitosan to Curdlan is 1:1/5-5, and the feeding quality of the crosslinker is 5-10% of total mass of the chitosan and Curdlan. The chitosan/ Curdlan blended membrane material of the invention can weaken the water absorption of the pure chitosan membrane and improves the air permeability of the membrane to cause the air permeability to reach higher requirements of artificial skin.

The present invention provides an external application wound repair liquid, which is characterized in that the repair liquid is prepared from sanguisorba, common bletilla tuber, japanese honeysuckle stem, and 75% ethanol. A preparation method of the external application wound repair liquid comprises: crushing the three herbs, uniformly mixing and filling into a container, adding the 75% ethanol, standing for a certain time, and carrying out repeated filtration to remove residues to obtain the external application wound repair liquid of the present invention. The external application wound repair liquid of the present invention can be used for various types of wounds, and has advantages of significant effect, simple preparation, easy use, and the like.

The invention provides a compound hemostasis medicine, namely a compound adrenal color hydrazone enteric capsule formulation or granular formulation, mainly containing adrenal color hydrazone, vitamin K1, vitamin C and pharmaceutic adjuvants. By using the invention, the defect lacking of blood coagulation function for the existing adrenal color hydrazone hemostasis medicine is solved to reduce blood capillary permeability and enable an injured blood capillary end to retract to realize hemostasis effect; vitamin K1 is used for affecting some blood coagulation factors and promoting or restoring blood coagulation process to speed up hemostasis; vitamin C containing synthetical collagen and histocyte is used for repairing injured blood capillary wall in time, stimulating blood coagulation function and promoting wound to heal; and the enteric formulation enables the medicine to release in intestines to effectively reduce stomach stimulation and adverse reaction of salicylic acid reaction caused by adrenal color hydrazone release in stomach. The invention also provides a method for preparing the compound adrenal color hydrazone enteric capsule formulation or granular formulation.

The invention discloses a plant functional drink with a heart and cerebral vessel protection function and a preparation method of the plant functional drink. The plant functional drink is prepared from raw materials in parts by weight as follows: 10-30 parts of dried ginger slices, 10-30 parts of dried garlic slices, 5-15 parts of dried lemon slices, 2-6 parts of dried radix glycyrrhizae slices, 2-6 parts of dried hawthorn fruit slices, 1-3 parts of barley tea, 1-3 parts of dried natto, 400-800 parts of water and 100-300 parts of apple cider vinegar. Solid raw materials are dried at 90-100 DEGC for 10-20 min, the dried raw materials are mixed in proportion and crushed to form powder of 30-80 mesh, the powder is uniformly mixed with water, the obtained mixture is heated to be boiled and kept boiling for 10-30 min, cooling is conducted, an extract solution obtained after separation is mixed with the apple cider vinegar in the weight ratio of (2-4): 1, sub-packaging and sterilization areperformed, and the functional drink product is obtained. The functional drink can also be prepared by directly heating the mixed powder with the water diluted apple cider vinegar for extraction. Thecost of the raw materials is low, the processing process is simple, and the plant functional drink has good effects on prevention and adjuvant therapy of cardiovascular and cerebrovascular diseases.

The invention discloses application of a CTSG (cathepsin G) cell factor in the preparation of medicaments to treat hepatic failure. Death of mass hepatic cells occurs during the course of hepatic failure; the CTSG cell factor helps overcome the aforementioned problem. CTSG JNK (c-Jun N-terminal kinase) is one of MAPK (mitogen-activated protein kinase) family members; JNK pathway can inhibit apoptosis of hepatic cells by regulating the expression of CTSG. The CTSG cell factor can be applied to the preparation of medicaments to treat hepatic failure to significantly increase biochemical indexesof a patient, reduce bilirubin level, lower aminotransferase, improve the coagulation function, inhibit cell apoptosis, promote the regeneration of hepatic cells and bile duct cells, prevent occurrence of fatal complications, such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome, extend the survival time of the patient significantly, and increase the survival rate.

The invention discloses an application of a PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the PPAR gamma cytokine. The problem that a large number of hepatocytes are dead in the course of hepatic failure can be solved by the PPAR gamma cytokine. PPAR gamma JNK (jun n-terminal kinase) is one of family members of MAPK, and a JNK pathway can inhibit hepatocyte apoptosis by regulating and controlling expression of PPAR gamma. Besides, damage of the liver and other organs is further aggravated due to the fact that serious liver metabolism dysfunction can appear in the hepatic failure process. PPAR gamma plays a pivotal role in lipid metabolism, and researches show that a PPAR gamma deficient type neonatal mouse has severe lipodystrophy shortly after birth.

The invention discloses an application of an AMPH (amphiphilic protein) cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the AMPH cytokine. On the basis of multi-center and large prospective cohort populations and samples, cross validation is executed from different angles with multiple techniques including transcriptome sequencing, multi-omics association analysis, qRT-PCR (quantitative reverse transcription-polymerase chain reaction), in-vivo validation in animal experiments and the like, and it is indicated that the AMPH cytokine can be applied to effective preparation of the hepatic failure treatment drug and the AMPH cytokine can cooperate with different solvents and stabilizers for producing drugs of different forms and dosages. Selectable administration modes in the using process comprise intravenous injection, intramuscular injection, hypodermic injection and oral administration. AMPH JNK (Jun N-terminal kinase) is one of MAPK family members, and a JNK pathway can inhibit hepatocyte apoptosis by regulating and controlling expression of AMPH.

The invention discloses application of a VSIG4 cytokine in preparation of a medicament for treating hepatic failure. The dose form of the medicament is an injection or a lyophilized powder injection or a suspension, the application temperature of the VSIG4 cytokine-containing medicament is 15-30 DEG C, and the humidity is 45-75%. The VSIG4 is a member of an ABCA superfamily and is mainly used formediating transmembrane transport of lipids and regulating metabolic disorders such as hepatocyte steatosis during hepatic failure. In the application of the VSIG4 cytokine in preparation of the medicament for treating hepatic failure, the biochemical indexes of patients can be significantly improved, the bilirubin level is lowered, the transaminase is reduced, the blood coagulation function is improved, the albumin level is raised, hepatocyte death is inhibited, regeneration of hepatocytes and bile duct cells is promoted, fatal complications such as major upper gastrointestinal duct bleeding,severe hepatic encephalopathy and hepatorenal syndromes are prevented, the survival time is significantly prolonged, and the survival rate is increased.

The invention discloses application of an IL-1R2 cell factor in preparing medicament for treating hepatic failure. The medicament comprises pharmaceutically acceptable excipients, antioxidants and carriers of the IL-1R2 cell factor. According to the invention, based on polycentric and prospective large-cohort population and samples, multiple technological methods of transcriptome sequencing, multi-omics correlation analysis, qRT-PCR, animal experiment in vivo validation and the like are adopted, cross validation is carried out from different angles, the IL-1R2 cell factor is found to be capable of being applied to the effective preparation of the medicine for treating the hepatic failure, and can be matched with different solvents and stabilizers to produce the medicines with different dosage forms and dosages. IL-1R2 is one of the members of ABCA superfamily, and has the main functions of mediating transmembrane transport of lipid and adjusting metabolic disorders such as hepatocyte fatty degeneration in the hepatic failure process.

The invention discloses application of a PRRT4 (proline rich transmembrane protein 4) cell factor in the preparation of drugs to treat hepatic failure. The drugs include PRRT4 cell factor pharmaceutically-acceptable excipients, antioxidants and vectors. The course of hepatic failure is involved with severe metabolic disorders, especially lipidosis. PRRT4 cell factor can overcome the difficulty; PRRT4 is associated with the functionality of mesenchymal stem cells and can promote the treatment of liver healing. In the application in the preparation of drugs to treat hepatic failure, PRRT4 cell factor can evidently increase biochemical indexes of a patient, lower bilirubin level, reduce aminotransferase, improve the coagulation function, increase the albumin level, inhibit apoptosis of hepatic cells, promote the regeneration of hepatic cells and bile tube cells, prevent fatal complications, such as upper gastrointestinal bleeding, severe hepatic encephalopathy and hepatorenal syndrome, evidently extend the survival time, and increase the survival rate.

The invention provides a medicined diet for people suffering from cancer in the perioperative period to eat, and relates to the field of medicined diets. The diet is prepared from, by weight, 500 parts of ginseng, 500 parts of manyflower solomonseal rhizomes, 500 parts of Chinese dates, 250 parts of donkey-hide glue, 500 parts of licorice roots, 500 parts of fructus lycii, 500 parts of ginger, 500parts of arillus longan, 500 parts of common yam rhizomes, 500 parts of hawthorn fruits, 3,000 parts of whey peptide powder, 5,000 parts of soybean peptide powder, 3,000 parts of fish collagen protein peptide powder, 150 parts of oligoprocyanidins (OPC), 50 parts of vitamin E, 250 parts of vitamin C, 0.125 part of vitamin A, 0.75 part of beta carotene, 0.005 part of vitamin D, 10 parts of vitaminB1, 10 parts of vitamin B2, 7.5 parts of vitamin B3, 5 parts of vitamin B6, 0.005 part of vitamin B12, 0.2 part of folic acid, 250 parts of fish oil and extracts, 1,000 parts of inulin, 1,000 parts of fructooligosaccharide, 400 parts of calcium, 150 parts of magnesium, 10 parts of zinc, 0.05 part of selenium and 10 parts of iron. The medicined diet can eliminate pulmonary vein thrombosis, resistinfection, improve the platelet coagulation function, reduce the blood loss, reduce the postoperative adhesion, and relieve pain and mental pressure of patients.

The invention discloses an application of an ABCA13 cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the ABCA13 cytokine, and the drug is in the form of an injection, a freeze-dried powder injection or a suspension. ABCA13 is one of ABCA superfamily members, mediates transmembrane transport of lipids and adjusts metabolic disorders such as hepatocyte steatosis and the like in the hepatic failure process, and ABCA13 is functionally related with mesenchymal stem cells and has a treatment effect for promoting liver repair. According to the application of the ABCA13 cytokine to preparation of the hepatic failure treatment drug, biochemical indexes of a patient can be remarkably improved, bilirubin level and transaminase are reduced, coagulation function and albumin level are improved, fatal complications such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome are prevented, the survival time is remarkably prolonged, and the survival rate is increased.

The invention discloses application of a DEFA4 cytokine to preparation of medicaments for treating liver failure. The medicaments include pharmaceutically acceptable excipients, antioxidants and carriers of the DEFA4 cytokine. DEFA4 is one of ABCA superfamily members, severe hepatic cell necrosis and apoptosis occur during the liver failure, and bone marrow-derived mesenchymal stem cells play an important role during liver repair. In the application to the preparation of the medicaments for treating the liver failure, the DEFA4 cytokine can significantly improve biochemical indexes of a patient, reduce the bilirubin level, reduce transaminase, improve the blood coagulation function, increase the albumin level, inhibit the hepatic cell death, promote the hepatic cell and bile duct cell regeneration, and prevent occurrence of fatal complications such as upper gastrointestinal bleeding, serious hepatic encephalopathy and hepatorenal syndrome, so that the survival time is significantly prolonged and the survival rate is increased.